Issued: Monday 14 January 2013, London UK - LSE Announcement
GlaxoSmithKline (GSK) plc today announced a regulatory submission to the US Food and Drug Administration (US FDA) for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world. GSK intends to submit a regulatory application in the European Union (EU) in early 2013.
About albiglutide
Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. GLP-1 is a peptide that is normally secreted from the gastrointestinal tract during a meal which in turn helps release insulin to control blood sugar elevations after eating. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or absent. GLP-1 is rapidly degraded while albiglutide has been developed to have a longer duration of action by being comprised of two copies of modified human GLP-1 fused in series to human albumin.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
GlaxoSmithKline Enquiries: | |||
UK Media enquiries: | David Mawdsley | +44 (0) 20 8047 5502 | (London) |
Sarah Spencer | +44 (0) 20 8047 5502 | (London) | |
David Daley | +44 (0) 20 8047 5502 | (London) | |
Catherine Hartley | +44 (0) 20 8047 5502 | (London) | |
Alex Harrison | +44 (0) 20 8047 5502 | (London) | |
US Media enquiries: | Stephen Rea | +1 215 751 4394 | (Philadelphia) |
Kevin Colgan | +1 919 483 2933 | (North Carolina) | |
Melinda Stubbee | +1 919 483 2510 | (North Carolina) | |
Mary Anne Rhyne | +1 919 483 0492 | (North Carolina) | |
Sarah Alspach | +1 202 715 1048 | (Washington, DC) | |
Jennifer Armstrong | +1 215 751 5664 | (Philadelphia) | |
Analyst/Investor enquiries: | Sally Ferguson | +44 (0) 20 8047 5543 | (London) |
Lucy Budd | +44 (0) 20 8047 2248 | (London) | |
Tom Curry | + 1 215 751 5419 | (Philadelphia) | |
Gary Davies | + 44 (0) 20 8047 5503 | (London) | |
James Dodwell | + 44 (0) 20 8047 2406 | (London) | |
Jeff McLaughlin | + 1 215 751 7002 | (Philadelphia) | |
Ziba Shamsi | + 44 (0) 20 8047 3289 | (London) |
Cautionary statement regarding forward-looking statements |
distributed by
|